Eli Lilly and vs Merck & Company at a glance
Both companies operate in the Health Care sector, so these figures are broadly like-for-like.
| Metric | LLY | MRK |
|---|---|---|
| Market cap | $1.06T | $378.46B |
| Price | $1,176.10 | $149.54 |
| P/E ratio (TTM) | 46.69 | 14.18 |
| P/B ratio (MRQ) | 36.31 | 4.92 |
| P/S ratio (TTM) | 14.78 | 3.98 |
| Revenue growth (1Y) | 44.70% | 1.31% |
| Return on equity (TTM) | 77.78% | 34.70% |
| Return on invested capital (TTM) | 34.50% | 22.71% |
| Gross margin (TTM) | 84.01% | 82.44% |
| Net margin (TTM) | 33.53% | 13.59% |
| Dividend yield (TTM) | 0.58% | 2.22% |
How they differ
Eli Lilly and is the larger company at $1.06T versus $378.46B — about 2.8x the size.
On trailing earnings, Merck & Company is the cheaper of the two at 14.18 against 46.69 for Eli Lilly and.
On sales, Merck & Company is the cheaper of the two at 3.98 against 14.78 for Eli Lilly and.
Eli Lilly and leads on revenue growth over the past year, 44.70% against 1.31%.
Eli Lilly and leads on return on invested capital, 34.50% against 22.71%.
Eli Lilly and leads on gross margin, 84.01% against 82.44%.
Merck & Company offers the higher yield at 2.22% against 0.58%.
Go deeper
Ratios describe the past. Whether either is worth owning depends on what you pay today.
Related comparisons
Other matchups involving Eli Lilly and or Merck & Company.